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Abstract This document presents the guidelines for the cere-
brospinal fluid (CSF) analysis and the determination of
oligoclonal bands (OCBs) as pivotal tests in neuroin
flammatory pathologies of the central nervous system. The
guidelines have been developed following a consensus
process built on questionnaire-based surveys, internet con-
tacts, and discussions at workshops of the sponsoring
Italian Association of Neuroimmunology (AINI) con-
gresses. Essential clinical information on the pathologies
in which the CSF analysis is indicated, and, particularly, on
those characterized by the presence of OCBs in the intra-
thecal compartment, indications and limits of CSF analysis
and OCB determination, instructions for result interpreta-
tion, and agreed laboratory protocols (Appendix) are
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Introduction
Cerebrospinal fluid (CSF) examination has produced and
keeps producing a large amount of data without substantial
standardization of procedures and techniques. The European
consensus on the CSF in the diagnosis of multiple sclerosis
(MS) [1] did not fully deal with the issue of procedure and
method standardization, as a subsequent publication
highlighted the need of identifying shared technical and inter-
pretative guidelines [2].
Since 2000, when the Italian Association of Neuroim-
munology (AINI) started promoting and managing the pro-
cess of standardization of methods and production of
guidelines, the judgment on the CSF analysis state of the
art moved from Bnearly sufficient,^ as reported by a 1995
survey of the Italian Society of Clinical Biochemistry [3],
to Bvery good,^ as extrapolated by the data of AINI exter-
nal quality control schemes between 2000 and 2014. In
summary, AINI centers (a) have applied the main method-
ological and procedural principles of the 1994 consensus
[1]; (b) currently use standardized and certified methods
for the determinations of albumin and IgG, which allow
the evaluation of blood-CSF barrier damage and intrathe-
cal IgG production, respectively; and (c) exploit the im-
provements of automation in isoelectric focusing (IEF)
techniques, used by a growing number of centers
(nothwithstanding that semi-automated instruments for
IEF use mini-gels that might perform suboptimally [4],
the AINI controls show that the quality of IEF runs has
been improving over years).
The area of CSF biomarkers needs standardization too. For
example, in MS, the lack of standardization is one of the main
reasons that prevent the entry of new claimed-to-be-effective
biomarkers into routine diagnostics. Other reasons include
cutoff values for discriminating between patients and con-
trols first optimized and then applied to the same cohorts,
thus artificially increasing test sensitivity and specificity,
and evaluations of single biomarkers instead of a set of
biomarkers, which could allow the real diagnostic power
of each of them. Accordingly, a recent and comprehensive
review maintains that no new MS biomarker have entered
routine diagnostics so far, although the CSF IgM
oligoclonal band (OCB) test is the most promising one
[5]. Again, the test has never undergone a thorough process
of validation and standardization.
Clinical and laboratory aspects
The evaluation of diagnostic performance of CSF tests is
complex for the following reasons: lumbar puncture is
usually not repeated, CSF volumes obtained are limited,
CSF samples from healthy controls are not easily avail-
able, and CSF abnormalities are disease-specific in very
few cases only. Therefore, in addition to low levels of
standardization, sensitivity and specificity of CSF tests
often show between-study moderate-high ranges of varia-
tion. All these considerations should dictate rational re-
quests for CSF analysis, which should follow thorough
evaluations of clinical settings and disease prevalences
(Bayes’ theorem). The main pathological conditions for
which the lumbar puncture is indicated are listed in
Table 1.
Urgent CSF analysis, which includes cell count, glucose,
and albumin determination in serum and CSF (CSF total pro-
tein as an alternative), is mandatory in suspected infectious
meningitis/meningoencephalitis.
Serum and CSF albumin determinations, with calculation
of albumin quotient, allow the most accurate measurement of
the degree of blood-CSF barrier permeability (Bblood-CSF
barrier damage^—which does not correspond to Bblood-
brain barrier damage^), and should replace CSF total pro-
teins in disorders characterized by intrathecal IgG produc-
tion at least [1].
IEF full standardization is inherently impossible due to
imponderable factors (gel conductivity, electrodes
soaking, lot-to-lot differences for ampholytes, electro
endosmosis phenomena, environment temperature/degree
of humidity).
Table 1 Indications for lumbar puncture for diagnostic purposes




Acute disseminated encephalomyelitis (ADEM)
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Autoimmune encephalitis
Testing for autoantibodies to surface membrane/synaptic neu-
ronal antigens is recommended for the differential diagnosis
of encephalitis [6, 7]. Testing CSF samples is mandatory for
the detection of anti-N-methyl-D-aspartate receptor (NMDA-
R) antibodies, since false negative results have been reported
in 14% of the cases testing serum samples only [8].
Preliminary findings suggest that repeated CSF titrations of
these antibodies can provide information on prognosis and
response to therapy [8].
Multiple sclerosis and oligoclonal bands
The 1994 consensus report contains seminal and still valid
principles for the CSF analysis ([1]; BAppendix^). One funda-
mental recommendation refers to the use of Bimmunofixation
after the isoelectric focusing step^ for OCB detection. In 2005,
the message was reinforced by a joint North American-
European consensus [9]. A Bfive-pattern scheme^ for IEF-
immunofixation test interpretation represents another essential
contribution to the OCB pattern interpretation [1]. Minor mod-
ifications to this scheme have been suggested ("Appendix").
The B2010 revised McDonald criteria^ for MS diagnosis
downplayed the diagnostic role of CSF testing, considered as
supportive criterion for the diagnosis of primary-progressive
MS only [10]. The criterion entails equivalence between CSF
OCBs and abnormal IgG Index values, although IgG Index is
less sensitive than OCBs for the intrathecal IgG synthesis
detection, and at risk of false positive results in the presence
of moderate/severe blood-CSF barrier damage [11]. The sub-
stantial exclusion of CSF analysis fromMS diagnostic criteria
has generated conflicting opinions (reviewed in [12]).
Notably, however, in patients with clinically isolated syn-
drome (CIS), CSF OCBs help define the risk of MS conver-
sion with 91% sensitivity and 94% specificity [13], with great-
er accuracy vs the criterion of dissemination in space on brain
MRI (70 vs 58%) and improvement of global diagnostic ac-
curacy [14]. Most importantly, the exclusion of alternative
diagnosis, which requires CSF analysis, is also fundamental
in CIS patients [15] and in general in patients with suspected
CNS inflammatory diseases.
On the prognostic side, the revived association between
absence of CSF OCB and benign MS prognosis [16], has
not been confirmed [17]. Moreover, some studies suggested
that CSF OCBs of the IgM isotype associate with (a) aggres-
sive MS forms [18], (b) better responses to immunotherapies
[19], (c) lower risks of developing progressive multifocal
leukoencephalopathy in patients on natalizumab [20], and
(d) higher probability of reaching EDSS scores of 3.0/4.0
10 years after onset [21]. The data are waiting for further
confirmation and wider consensus before IgMOCB test enters
routine clinico-laboratory practice [22].
Neuromyelitis optica spectrum disorders
CSF is less sensitive than serum for the detection of AQP4-
IgG [23]. Testing CSF samples is restricted to seronegative
NMOSD patients comorbid for other autoimmune diseases,
as these systemic diseases possibly associate with circulating
autoantibodies that can interfere with anti-AQP-4 antibody
detection [24].
Creutzfeldt-Jacob disease
Western blot for CSF protein 14.3.3 determination is the
reference test for the diagnosis of Creutzfeldt-Jacob dis-
ease [25]. Tau protein ELISA, which allows quantitative
measurements, has high specificity and specificity (>90%)
[26], and could complement or replace the semi-
quantitative Western blot technique for protein 14.3.3
determination.
Alzheimer disease
A consensus paper by the BAlzheimer’s Biomarkers
Standardization Initiative^ on one hand insisted on the need
for standardization of biomarkers in AD and, on the other
hand, recommended the routine practice of measuring the
CSF concentrations of protein tau, hyperphosphorylated pro-
tein tau, and amyloid beta1–42 in patients with early onset
dementia, prodrome of the disease, and atypical forms of
AD [27]. Today, a good level of standardization has been
reached thanks also to international quality control schemes.
The typical modifications of the three biomarkers allow the
diagnosis of AD in the initial phases, whereas normal values
exclude the disease [27]. Regrettably, how an early diagnosis
of AD may be relevant in prognostic and therapeutic terms is
still rather unclear.
Amyotrophic lateral sclerosis
CSF neurofilaments are increasingly emerging as important
biomarkers of axonal damage. Their determination is useful
for the differential diagnosis of motor neuron diseases, and
therefore, they should be included in the diagnostic workup
of the disease [28].
Inflammatory neuropathies
Increased values of CSF total proteins or albulmin quotient
with normal CSF cell counts (albumino-cytologic
dissociation) are often found in patients with Guillain-
Barré syndrome [29] or chronic inflammatory demyelinat-
ing polyradiculoneuropathy, in which they are considered
one of the supportive criteria for the diagnosis [30].
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1.1 Lumbar puncture is usually performed in the morn-
ing on fasting patients.
1.2 CSF should be collected in sterile siliconized-glass/
polypropylene tubes (glass tubes favor monocyte
adhesion).
1.3 Volumes of lumbar-drawn CSF should be standard-
ized (4–5 mL) and preferably collected in a single
tube, because of the following:
i) There is a protein concentration gradient be-
tween the first and the last milliliters of drawn
CSF [31]; standardized CSF volumes allow
accurate comparisons on follow-up analysis
and in research settings.
ii) CSF cell collection is maximized.
1.4 Whenmicrobiological tests are required, top priority
is given to sterility and one additional single CSF
aliquot should be collected.
1.5 Use of atraumatic needles (e.g., Sprotte® 25S) can
minimize the frequency of post-lumbar puncture
headache and allow safe collection of up to 20 mL
of CSF [32], useful for cell studies.
1.6 A blood sample is always taken simultaneously with
the lumbar puncture.
1.7 Paired blood and CSF samples should be sent to the
laboratory as soon as possible (within 2 h after
collection).
1.8 Procedures for sending samples to external labora-
tories (microbiology, pathology, etc.) should be
agreed in advance.
1.9 Blood samples should not be hemolyzed or lipemic.
1.10 In cases of traumatic lumbar puncture or suspected
subarachnoid hemorrhage:
i) Collect CSF samples in three tubes.
ii) Use the least contaminated tube for analysis.
iii) A not-decreasing-into-three-tube contamina-
tion could indicate subarachnoid hemorrhage,
without excluding traumatic lumbar puncture.
1.11 Blood-contaminated CSF samples:
i) If obtaining a non-contaminated sample is im-
possible, blood-contaminated CSF samples
are analyzed nonetheless (if there are no clots
and they are clear and colorless after
centrifugation).
ii) Correcting CSF parameters taking into ac-
count erythrocyte numbers is inaccurate. No
abnormal test results argue for a Bnormal CSF
sample,^ whereas abnormalities require criti-
cal interpretations in relation to other
paraclinical findings and each clinical case.
iii) Samples should be excluded from research
protocols.
2.0 Analytical procedures
2.1 Visual assessment and spectrophotometric analysis
2.1.1 Assess appearance and color before and after cen-
trifugation at 1500–3000 rpm (about 500×g) for
10 min.
2.1.2 For collecting cell pellets, centrifuge CSF samples
with swinging-bucket centrifuges.
2.1.3 Qualitative scales should be used for appearance
(e.g., Bcrystal clear,^ Bcloudy,^ Bturbid^) and color
(Bcolorless,^ Bxantocromic,^ Berythrocromic^).
2.1.4 Spectrophotometry should be performed only in
suspected subarachnoid hemorrhage or to demon-
strate previous hemorrhages [33]. A normal brain
CT scan does not rule out subarachnoid
hemorrhage.
i) Use centrifuged CSF samples.
ii) Spectrophotometric peaks of 415 and
460 nm indicate high total protein levels
(usually due to blood-CSF-barrier damage).
iii) Spectrophotometric peaks of hemoglobin
(Hb) degradation products: the early metab-
olites (4–8 days) oxidized- and meta-Hb:
415, 540, and 580 nm indicate recent, and
the late metabolites (15–20 days) bilirubin
and bilirubin compounds: 350, 400 and
460 nm, late subarachnoid hemorrhage.
2.2 CSF cells
2.2.1 CSF cell analysis should be performed within 2 h
after CSF collection [34].
2.2.2 Use at least 100 μL of CSF sample for cell count,
after gentle agitation of the tube.
2.2.3 Allowed counting chambers: Fuchs-Rosenthal,
Bürker, and Nageotte.
2.2.4 Turk’s solution (1:1 dilution) helps lyse erythro-
cytes and counterstain CSF cells.
2.2.5 CSF cell identification: after the first CSF sample
centrifugation, the resulting cell pellets are proc-
essed with cytocentrifuges (cytospins) or sedimen-
tation chambers (search for tumor cells should per-
tain to anatomical pathologists).
2.2.6 Fix cell pellets with 10% formaldehyde (50 μL)
for later analysis.
2.2.7 Stain CSF cells with May-Grünwald-Giemsa (dif-
ferential count).
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2.2.8 Morphologic CSF cell analysis is mandatory in
suspected meningeal carcinomatosis even in the
absence of pleocytosis.
2.2.9 Reporting leukocyte differential counts is optional,
unless required by the clinical suspicion.
2.2.10 Flow cytometers, useful for counting and pheno-
typing CSF cells, are indispensable for assessing
B cell clonality in suspected CNS lymphomas.
2.2.11 In blood-contaminated CSF samples, the number
of erythrocytes adds no information on the degree
of blood-derived cell contamination.
2.3 Biochemical analysis
2.3.1 Perform biochemical analysis on supernatants of
centrifuged CSF samples.
2.3.2 Test paired serum and CSF samples.
2.3.3 Basic tests (glucose, albumin, IgG)
2.3.3.1 The percentage of serum-to-CSF glucose trans-
fer (CSF glucose/serum glucose × 100) should
replace glycorrachia (CSF glucose levels phys-
iologically depend on serum glucose levels).
2.3.3.2 Glucose is measured with colorimetric assays
in automated analyzers.
2.3.3.3 Blood-CSF barrier damage can be expressed
as albumin ratio (Albserum/AlbCSF), or albumin
quotient (AlbCSF/Albserum) ×10
3 or ×102 [35].
2.3.3.4 Degree of blood-CSF barrier damage can be
semi-quantitatively expressed: Bnormal^ for
albumin quotient values up to 0.7%; Bmild,^
up to 2.0%; and Bmoderate,^ up to 5.0%;
Bsevere,^ >5.0% [36].
2.3.3.5 To reduce imprecision, albumin and IgG in
serum and CSF should be measured with the
same method and on the same analytical run.
2.3.3.6 Intrathecal IgG synthesis should be calculated
with non-linear functions, such as Reiber for-
mula [11], which take into account the blood-
CSF barrier damage. IgG Index/Link index
can yield false positive results in the presence
of moderate/severe blood-CSF barrier damage
[36].
2.3.3.7 Allowed methods for albumin and IgG mea-
surement are as follows: nephelometry, turbi-
dimetry, and radial immunodiffusion.
2.3.4 Other tests
2.3.4.1 CSF lactate determination is optional (useful in
suspected septic meningitis/meningoencephali-
tis, when antibiotic therapy performed before
the lumbar puncture could have normalized
CSF glucose/serum glucose ratio). Due to
lactate hydrophobicity, CSF lactate concentra-
tions are independent from serum levels.
2.3.4.2 CSF IgA and IgM determinations are optional
(no specific indications).
2.3.5 Calculation of antigen-specific antibody intrathe-
cal synthesis
2.3.5.1 Starting from 3 to 4 weeks after onset of viral
meningoencephalitis formulas for virus-
specific antibody intrathecal synthesis can be
positive and diagnostically useful [37]. In
neuroborreliosis and West Nile virus, enceph-
alitis antibody determinations are diagnostical-
ly mandatory, since PCRs are often negative
[38, 39].
2.3.5.2 In suspected MS, testing for anti-measle-
rubella-varicella antibodies in serum and
CSF (MRZ-reaction) should be restricted to
atypical cases [40].
2.3.5.3 Tests for antigen-specific antibodies should be
preferably performed in specialized laborato-
ries of Centers of Infectious Diseases.
2.3.5.4 Antigen-specific antibody intrathecal synthe-
sis can be calculated as follows [41]:
i) Determine total IgG concentration in
serum and CSF.
ii) Dilute serum samples so that serum to-
tal IgG concentration equalizes CSF to-
tal IgG concentration.
iii) Test serum and CSF samples on ELISA
for antigen-specific IgG; express results
in optical density (OD); dilute and re-
test samples if absorbance values fall
outside the linear parts of the standard
curves.
iv) Antigen-specific antibody index:
ODCSF/ODserum ratio >1.5–2.0 indi-
cates antigen-specific antibody intra-
thecal synthesis (the cutoff takes into
account imprecision in total IgG and
antigen-specific IgG measurements).
2.3.5.5 Immuno-affinity capillary blotting can be used
for detecting antigen-specific OCBs [42]. It is
labor-intensive, requires large amounts of viral
proteins/peptides/lysates, and results of limited
usefulness in routine practice.
2.4 Determination of oligoclonal IgG bands
2.4.1 Agarose or polyacrylamide gels for IEF (pH range,
3.0–10.0; standard size, intermediate size (midi-
gels), and small size (mini-gels)), either home-
made or commercial, are allowed.
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2.4.2 Automated and non-automated IEF apparatus are
allowed.
2.4.3 Equal amounts of paired serum and CSF IgG
should be loaded on the gel adjacent lanes.
2.4.4 Amounts of the loaded-onto-the-gel serum and
CSF IgG vary on the basis of different sensitivities
of the staining methods (CSF sample concentra-
tion not allowed).
2.4.5 Refer to published protocols for blotting and IgG-
specific detecting procedures [43]. For semi-
automated instruments, follow manufacturer’s
instructions.
2.4.6 Sensi t ive s ta in ing techniques for IgG
immunodetection are mandatory (e. g., peroxi-
dase, avidin-biotin, chemiluminescence).
2.4.7 pH standards are useful for IEF set up.
2.4.8 High voltages require efficient IEF plate cooling
systems. Stop IEF runs when low values of amper-
age are stable for 10 min. Early stopping can cause
partial OCB focalization, whereas excessively
protracting runs OCB distortions.
2.4.9 Agarose gels: regularly dry the cathodal area,
where electroendosmosis phenomena yield water,
to prevent lack of OCB focalization and OCB
distortions.
2.5 Interpretation of oligoclonal IgG band patterns
2.5.1 IEF interpretation, not requiring densitometers
(human eyes are better in contrast discrimination),
should be performed by two experienced opera-
tors. Particular attention should be paid to artifac-
tual bands produced by the lack pH gradient ho-
mogeneity, due to regional weakness in conduc-
tivity within the gel; OCB-negative controls allow
the recognition of such bands.
2.5.2 Adopt the following pattern classification: [1]
i) Type 1, diffuse polyclonal IgG distribution
in both CSF and serum (absence of intrathe-
cal IgG synthesis, normal pattern).
ii) Type 2, unique-to-CSF OCBs (presence of
intrathecal IgG synthesis, typical of
s u b a c u t e / c h r o n i c CNS immuno -
inflammatory processes with immune re-
sponse intrathecal compartmentalization).
iii) Type 3, the so-called mixed pattern, unique-
to-CSF OCBs in addition to OCBs equal in
serum and CSF (presence of intrathecal IgG
synthesis, typical of acute/subacute CNS
immuno-inflammatory processes with im-
mune response persistence in the systemic
compartment).
iv) Type 4, the so-called mirror pattern, OCBs
equal in serum and CSF (absence of
intrathecal IgG synthesis, typical of systemic
immuno-inflammatory processes, with or
without CNS involvement, andwith systemic
production of OCBs).
v) Type 5, the paraprotein pattern, OCBs equal
in serum and CSF similarly to pattern 4, but
with regular and periodic spacing and de-
creasing intensity (absence of intrathecal
IgG synthesis, presence of monoclonal
gammopathy).
2.5.3 A positive OCB test is defined by the presence of
at least two (Boligo^) bands.
2.5.4 Not considered in the 1994 consensus [1], single
CSF bands, with or without bands equal in serum
and CSF can be detected and should be reported.
Theymight associate withMS [44–46]. Follow-up
CSF analysis is advisable.
2.5.5 Given the limits of human eyes, the interpretation
of Bfaint bands^ cannot be standardized. Retesting
increased amounts of IgG (although it entails in-
creases of polyclonal IgG background too), and
follow-up CSF analysis is advisable.
2.5.6 Moderate/severe blood-CSF barrier damage or
blood-contaminated CSF samples can reduce the
chance of detecting OCBs, due to the increased
amount of blood-derived polyclonal IgG (for be-
ing detectable, OCBs have to emerge from poly-
clonal IgG backgrounds).
2.5.7 Not considered in the 1994 consensus [1], OCBs
equal in serum and CSF, but more intense in the
CSF might indicate intrathecal IgG synthesis, as
equal amounts of serum and CSF IgG are com-
pared. However, imprecision can affect IgG mea-
surements and sample dilutions, thus making un-
reliable the comparison of different intensity of
CSF OCBs vs the serum counterparts. Follow-up
CSF analysis is advisable.
2.5.8 Inter-laboratory reproducibility for OCBs is low
[2, 47], thus limiting multicenter studies.
3.0 Quality control and specimen storage
3.1 Biochemistry and proteins
3.1.1 Internal controls should be included (e.g., pooled
CSF samples).
3.1.2 External quality controls: follow the rules for lab-
oratory accreditation.
3.2 Isoelectric focusing
3.2.1 Include positive (e.g., serum with monoclonal
IgG) and negative controls.
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3.2.2 External quality controls for OCBs should be
planned at least yearly (e.g., AINI external quality
control schemes).
3.2.3 Serum and CSF samples should be stored in ali-
quots at −20 °C, preferably at −80 °C.
4.0 Report
4.1. The following information should be reported:
4.1.1 Date and hour of lumbar puncture.
4.1.2 Anatomical site of origin of the CSF sample (lum-
bar, ventricular, cystic).
4.1.3 Test tube on which the analysis is performed (e.g.,
unique, third).
4.1.4 Appearance and color of the CSF before and after
centrifugation.
4.1.5 Methods used for biochemico-immunological
determinations.
4.1.6 Type of chamber for CSF cell counting/flow
cytofluorimeter.
4.1.7 Reference values for each item.
4.1.8 Morphological description of CSF and IEF
interpretation.
4.1.9 Comments (optional).
4.2 The reference values of CSF parameters should be
assessed in appropriate control groups (diseased pa-
tients and healthy controls) for each laboratory.
Reference values from published data can be adopted
for both adult and pediatric patients. In adults with age
>60 years, the physiological decrease of the CSF flow
causes increases in albumin quotient (AQ) values,
which can be thus non-indicative of blood-CSF barrier
damage. For a more precise definition of the AQ upper
reference limit, the formula 'AQ = age/25 + 8' has been
proposed [48].
4.3 OCBs might be semi-quantitatively evaluated as fol-
lows: (a) single band; (b) two bands; (c) some bands
(n = 3–6); (d) numerous bands (n > 6).
4.4 Reports may contain the sentence: BThis laboratory
follows procedures and methods standardized on be-
half of the Italian Association of Neuroimmunology
(date of the latest revision) and participates in the ex-
ternal quality control schemes promoted by the
Association.^
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